bims-glumda Biomed News
on CGM data in management of diabetes
Issue of 2025–06–08
thirteen papers selected by
Mott Given



  1. Endocr Pract. 2025 Jun 02. pii: S1530-891X(25)00898-5. [Epub ahead of print]
       OBJECTIVES: Low and very-low carbohydrate eating patterns can improve glycemia in people with type 2 diabetes (T2D). Continuous glucose monitoring (CGM) may also help improve glycemic outcomes, like time in range (TIR). This research evaluated differences in diabetes-related outcomes when people with T2D used CGM or blood glucose monitoring (BGM) to support dietary choices and medication management for six months during a virtual, medically supervised ketogenic diet program (MSKDP). Three-month primary outcomes are published, and here we report six-month follow-up outcomes.
    METHODS: The IGNITE study (Impact of Glucose moNitoring and nutrItion on Time in rangE) randomized participants to use CGM (N=81) or BGM (N=82) to support care during six months in a MSKDP. Glycemia, diabetes medications, dietary intake, ketones, and weight were assessed at baseline (Base) and month 6 (M6); differences between and within arms were evaluated.
    RESULTS: Adults (N=163) with mean (SD) T2D duration of 9.7 (7.7) years and HbA1c of 8.1% (1.2%) participated. From Base to M6, TIR improved 61% to 87% for CGM and 63% to 88% for BGM (p<0.001), with no difference in changes between arms (p=0.99). HbA1c decreased at least 1.3% from Base to M6 in both arms (p<0.001). Diabetes medications were de-intensified in both arms based on medication effect scores (p<0.01). Energy and carbohydrate intake decreased (p<0.001) and participants in both arms had clinically meaningful weight loss (p<0.001).
    CONCLUSIONS: The CGM and BGM arms achieved similar and significant improvements in glycemia and other diabetes-related outcomes after six months in this MSKDP.
    Keywords:  carbohydrate; continuous glucose monitoring; diet; nutrition; time in range; type 2 diabetes
    DOI:  https://doi.org/10.1016/j.eprac.2025.05.746
  2. Clin Transplant. 2025 Jun;39(6): e70202
       INTRODUCTION: Targets for continuous glucose monitoring (CGM) are well established for type 1 and type 2 diabetes. In total pancreatectomy with islet autotransplantation (TPIAT), stricter glycemic targets are needed to avoid metabolic stress on transplanted islets, but no guidelines exist for CGM targets.
    METHODS: We aimed to determine CGM targets for TPIAT clinical management by associating CGM metrics with goal hemoglobin A1c (HbA1c) ≤ 6.5%. Targets for time in range (TIR) 70-140, TIR 70-180, mean CGM glucose, and time in hyperglycemia (>140, >180, >250 mg/dL) were chosen to give good sensitivity and specificity for identifying HbA1c ≤6.5%.
    RESULTS: We included 256 pairs of 14-day CGM metrics with a concurrent HbA1c value (n = 82 patients, age 35 [IQR 19-46] years at surgery, 70% female) who were ≥0.5 years post TPIAT (median 4.1 years) and wearing Dexcom G6. Most patients had more than one HbA1c and corresponding CGM available (median 2 [IQR 1-4] per patient).
    CONCLUSION: We found that TIR 70-140 ≥ 50% and TIR 70-180 mg/dL ≥ 75% may be reasonable minimum targets for patients and providers using CGM data to manage diabetes long-term after TPIAT. Failure to meet these targets should prompt starting or adjusting insulin therapy, especially if hypoglycemia is not a concern.
    Keywords:  autologous; blood glucose; clinical targets; continuous glucose monitoring (CGM); diabetes; glycated hemoglobin; pancreatectomy; total pancreatectomy with islet autotransplantation (TPIAT); transplantation
    DOI:  https://doi.org/10.1111/ctr.70202
  3. Diabetes Technol Ther. 2025 Jun 05.
      Aims: We investigated the association between continuous glucose monitoring (CGM) metrics and clinical outcomes in the nonintensive care unit (non-ICU) setting. Methods: In this observational cohort study, patients on non-ICU floors wore blinded Dexcom G6 Pro CGM. CGM metrics and occurrence of CGM-detected severe hypoglycemia were measured. Clinical data, including infection, diabetic ketoacidosis, renal replacement therapy, thrombosis, and 30-day post-discharge readmissions and emergency department (ED) visits were identified from the medical record and participant phone interview. Multivariate regression assessed predictors of CGM-detected severe hypoglycemia and the associations between CGM metrics and clinical outcomes. Regression models using CGM data or reference glucose data were compared with receiver operating characteristic (ROC) curves. Results: A total of 326 hospitalized adults were enrolled with median % time in range 70-180 mg/dL 44.5% (17.1, 70.2%), % time above range >180 mg/dL 54.8% (28.8, 82.3%), and % time below range 0.6% (0, 0.2%). Predictors of severe hypoglycemia included type 1 diabetes, female gender, lower admission hemoglobin, lower A1c, and longer hospital stay. Regression analyses demonstrated an association of 30-day ED visits with increased %TAR (P = 0.01). ROC curves showed models using CGM data or reference data predicted clinical outcomes similarly. Conclusions: CGM can be useful in identifying patients at risk of inpatient hypoglycemia and 30-day ED visits.
    Keywords:  continuous glucose monitoring; hospital; hypoglycemia; inpatient; outcomes
    DOI:  https://doi.org/10.1089/dia.2024.0628
  4. Diabetes Res Clin Pract. 2025 May 29. pii: S0168-8227(25)00300-6. [Epub ahead of print]226 112286
       AIMS: Time above range obtained through continuous glucose monitoring (CGM) is a useful marker for identifying individuals at higher risk of developing diabetes. We aimed to determine the optimal cutoff for the percentage of time glucose exceeds a threshold to predict diabetes onset.
    METHODS: Prospective observational study involving CGM in individuals without diabetes. Individuals who completed CGM and were not diagnosed with diabetes at baseline were followed for a median of 10.8 years.
    RESULTS: Among 513 individuals (median age: 46; range: 18-82), 42 developed diabetes during follow-up. Individuals who developed diabetes were older (median age [IQR]: 53 [45-63] vs. 45 [35-57] years; p < 0.001) and had a higher BMI (32.2 [28.9-35.2] vs. 26.8 [23.8-30.3] kg/m2; p < 0.001) compared to those who did not. The most significant differences between those who developed diabetes and those who did not were observed when we set a cutoff of ≥ 130 mg/dL for at least 10 % of monitoring time.
    CONCLUSIONS: CGM provides highly useful information for predicting type 2 diabetes. In healthy individuals, exhibiting glucose levels at or above 130 mg/dL for over 10 % of the time over at least two monitoring days show a higher risk of developing type 2 diabetes.
    Keywords:  Health care; Incidence; Prediction and prevention; Type 2 diabetes; continuous glucose monitoring (CGM)
    DOI:  https://doi.org/10.1016/j.diabres.2025.112286
  5. NASN Sch Nurse. 2025 Jun 06. 1942602X251341902
      Continuous glucose monitoring (CGM) offers reliable glycemic measurements and improved health outcomes for pediatric patients with type 1 diabetes. With CGM use becoming the new pediatric standard of care for type 1 diabetes management, it is increasingly common for children with diabetes to arrive in school wearing CGM devices. School nurses' lack of familiarity with this new technology can lead to dangerous methods of assessment, interpretation, and treatment of sensor glucose results. An evidence-based, standardized CGM protocol and educational module were developed to increase confidence among school nurses in providing accurate and safe treatment decisions for students with type 1 diabetes. This project highlights the potential of a standardized assessment tool for school nurses to increase their confidence in caring for students with CGMs at school, informing future integration of CGM training into clinical practice guidelines.
    Keywords:  diabetes; health assessment; medical technology/device; nursing assessment; school nurses
    DOI:  https://doi.org/10.1177/1942602X251341902
  6. Diabetes Care. 2025 Jun 04. pii: dc250291. [Epub ahead of print]
    CLVer Study Group
       OBJECTIVE: Continuous glucose monitoring (CGM) measures could be a surrogate for stimulated C-peptide outcomes in type 1 diabetes trials.
    RESEARCH DESIGN AND METHODS: CGM and mixed-meal tolerance test-derived C-peptide measures at time points out to 52 weeks after diagnosis were compared in 103 children.
    RESULTS: At 52 weeks, CGM metrics moderately correlated with C-peptide area under the curve. The highest Spearman correlations were for time-in-range 70-180 mg/dL, time <70 mg/dL, and glucose coefficient of variation (0.45, -0.33, and -0.58, respectively; the multivariate model using these three metrics had a slightly higher correlation of 0.63). For predicting peak C-peptide concentrations ≥0.2 pmol/mL, this combination had a sensitivity of 68.4% and specificity of 75%.
    CONCLUSIONS: CGM measures correlated with stimulated C-peptide measures; however, the strength of the correlations and sensitivity and specificity of CGM-derived measures were not great enough to replace C-peptide measures in clinical trials.
    DOI:  https://doi.org/10.2337/dc25-0291
  7. Diabetes Ther. 2025 Jun 04.
      The association of sleep apnoea with insulin resistance and type 2 diabetes mellitus (T2DM) is well studied. However, little is known on the impact of sleep apnoea on glycaemic variability (GV). Continuous glucose monitoring (CGM) systems shed light on GV not only during sleep but throughout the day among people with or without diabetes mellitus (DM) and obstructive sleep apnoea syndrome (OSAS). In this narrative review, we aimed to summarise the evidence on the role of CGM in assessing GV among individuals with sleep apnoea. Articles related to CGM use among individuals with OSAS were included. Emerging data suggests a significant impact of OSAS on glucose metabolism during sleep and wakefulness. Of note, OSAS affects GV irrespective of glycaemic status. Moreover, the severity of OSAS has been associated with increased GV. As GV triggers oxidative stress, it contributes to adverse outcomes in people with diabetes and/or OSAS. Interestingly, a beneficial effect of continuous positive airway pressure (CPAP) treatment on blood glucose and on GV in individuals with both T2DM and OSAS has emerged, but evidence is conflicting. Additionally, among pregnant women with gestational diabetes and sleep-disordered breathing, CGM could detect nocturnal hyperglycaemic episodes, improving glycaemic control and perinatal outcomes. Future studies are needed to investigate the exact impact of OSAS treatment on GV.
    Keywords:  Continuous glucose monitoring; Continuous positive airway pressure; Diabetes mellitus; Glycaemic variability; Sleep apnoea syndrome; Sleep disordered breathing
    DOI:  https://doi.org/10.1007/s13300-025-01756-1
  8. Sci Diabetes Self Manag Care. 2025 Jun;51(3): 333-344
      PurposeThe purpose of the 2-phase study was to determine patient/family and clinician design preference, usability, and comprehension of ambulatory glucose profile (AGP) reportsMethodsA cross-sectional research design employing 2 phases was conducted. Patients and parents (n = 139) reviewed an educational guide and AGP report during a clinician consultation. They were directed to identify glucose trends before answering a design preferences and usability survey. Clinicians (n = 17) completed questionnaires about patients and personal experiences, design preferences, and expected future usability. Further study of the AGP (n = 21) evaluated a draft display AGP continuous glucose monitoring (CGM) + pump report, enhanced after the aforementioned blood glucose monitoring (BGM) and CGM survey through interviews using both scripted and unscripted questions.ResultsPatients identified glucose trends/patterns in all AGP reports (100% BGM; 98% CGM; 95% CGM + pump). Patients and clinicians felt that the single-page report added value both in and outside of the clinic, preferred this standardized data view compared to traditional device-specific reports, and saw value in the AGP combination of statistics and graphs. Insulin data were seen as useful but increased the difficulty of report interpretation; only 38% were able to accurately interpret the data and make self-treatment recommendations.ConclusionsPatients feel that the AGP report (BGM, CGM, CGM + pump) is useful for identifying new glucose patterns/trends. Patients report more confidence in making self-care adjustments (behavioral, lifestyle, and treatments) using the AGP report. For shared decision-making, the AGP report serves both patients' and clinicians' needs.
    DOI:  https://doi.org/10.1177/26350106251337486
  9. Diabetes Technol Ther. 2025 Jun 02.
      Neonatal hypoglycemia (NH) is potentially life-threatening and can lead to long-term neurological sequelae. We retrospectively assessed the association between maternal glycemia in women with type 1 diabetes (T1D) and NH. Continuous glucose monitoring data from 60 mothers, alongside routine capillary blood glucose measurements from their neonates, were analyzed. The analyses used two clinically recognized thresholds for NH (<2.2 mmol/L and <2.6 mmol/L). In total, there were 25 neonates (41.7%) with NH <2.6 mmol/L and 19 neonates (31.7%) with NH <2.2 mmol/L. Neonates with NH <2.2 mmol/L were born at a lower gestational age (37.0 [35.9, 37.7] vs. 37.6 [37.0, 38.4] weeks, P = 0.019), a higher proportion was exposed to antenatal corticosteroids (31.6% vs. 7.3%, P = 0.014), and a higher proportion required admission to the neonatal intensive care unit (42.1% vs.12.2%, P = 0.009). Similar associations were observed for NH <2.6 mmol/L, although admission rates to the neonatal intensive care unit did not reach statistical significance. Mixed-effects logistic regression analysis identified percentage time above range (odds ratio [OR] 1.047, 95% confidence interval [CI] 1.007-1.087, P = 0.01) and percentage time in range (OR 0.951, 95% CI 0.914-0.989, P = 0.01) as significantly associated with NH <2.2 mmol/L. Our data suggest that careful optimization of glycemia early in pregnancy, rather than in the final trimester alone, may help minimize the risk of NH in infants born to mothers with T1D.
    Keywords:  maternal hyperglycemia; neonatal hypoglycemia; pregnancy; real-time continuous glucose monitoring; type 1 diabetes
    DOI:  https://doi.org/10.1089/dia.2024.0477
  10. Diabet Med. 2025 Jun 03. e70052
       AIMS: To characterize changes in continuous glucose monitoring (CGM)-derived time in tight range (TIR) measures in individuals with prediabetes or non-insulin-treated type 2 diabetes undergoing dietary weight loss intervention and to quantify the association between weight loss and TIR improvement.
    METHODS: Data from the Personal Diet Study, a 6-month behavioural weight loss intervention in adults with prediabetes or non-insulin-treated type 2 diabetes [HbA1c ≤ 8.0% (64 mmol/mol), managed with diet alone or with metformin], was analysed. Participants wore a CGM for a maximum of 2 weeks at baseline and 6 months. Changes in overall, daytime (06:00 h-23:59 h) and overnight (00:00 h-05:59 h) time in 54-140 mg/dL or 3.0-7.8 mmol/L (TIR54-140), 70-140 mg/dL or 3.9-7.8 mmol/L (TIR70-140) and >140 mg/dL or >7.8 mmol/L (TAR>140) were analysed. The association between weight change and TIR change adjusted for demographic and clinical covariates was computed using linear regression.
    RESULTS: Baseline and 6 months CGM data from 76 participants (63 ± 8 years, 62% female, 64% White, BMI 33 ± 5 kg/m2, HbA1c 5.8 ± 0.6%) were analysed. Overall TIR54-140 increased (3.3% [0.3, 6.3]%; p = 0.03), with improvement in daytime (3.8% [0.9, 6.8]%; p = 0.01) but not overnight TIR54-140 (2.0% [-2.2, 6.1]%; p = 0.36). In adjusted analysis, every 5% points of weight loss was associated with a 3.2% points increase in overall TIR54-140 (p = 0.016), driven by a 3.5% points increase in daytime TIR54-140 (p = 0.006). Similar associations were found for TAR>140 but not TIR70-140. There were no associations between weight loss and change in any overnight TIR measure.
    CONCLUSION: Weight loss was associated with improved daytime TIR54-140 and TAR>140 in individuals with prediabetes and non-insulin-treated type 2 diabetes undergoing dietary intervention. The daytime time in tight range measures can complement traditional markers like HbA1c, offering a more comprehensive view of glycaemic variations during dietary weight loss programmes for individuals with prediabetes and type 2 diabetes not on insulin.
    Keywords:  type 2 diabetes
    DOI:  https://doi.org/10.1111/dme.70052
  11. Am J Perinatol. 2025 Jun 03.
       OBJECTIVE: The use of continuous glucose monitors (CGM) and insulin pumps as revolutionized the care of patients with type 1 diabetes (T1D). Few data are available regarding use of diabetes technology use in the pregnant T1D population. This study was conducted to evaluate temporal trends of diabetes technology use and predictors of use among pregnant individuals with TID in the United States from 2009 to 2020.
    METHODS: MarketScan® Research Databases from 2009 to 2020 were used to identify pregnant individuals with T1D who were and were not using CGM and/or insulin pumps. Joinpoint regression analysis was used to estimate average annual percent change (AAPC) in diabetes technology use over time. Unadjusted and adjusted log-linear Poisson regression models were developed to assess the associations between the outcomes of CGM and insulin pump use and demographic and clinical predictors. Associations were reported as adjusted risk ratios (ARR) with 95% confidence intervals (CI).
    RESULTS: Among 9,201 pregnancies with T1D, CGM use increased from 2.3% in 2009 to 13.7% in 2020 (AAPC 13.9%, 95% CI 11.7-17.1%), while insulin pump use remained unchanged from 10.9% in 2009 to 11.8% in 2020 (AAPC -2.4%, 95% CI -4.4-0.4%). Medicaid insurance and obesity were associated with lower likelihood of CGM use and insulin pump use, while high obstetric comorbidity index score was associated with higher likelihood of insulin pump use (ARR 1.26, 95% CI 1.05-1.51).
    CONCLUSION: From 2009 to 2020, CGM use among pregnant individuals with T1D increased, while insulin pump use remained unchanged. Use varied by patient demographic and clinical factors, most notable for lower likelihood of CGM use and insulin pump use with Medicaid insurance. Although CGM use increased over time, overall CGM use remained lower than expected despite the known benefits of CGM use in improving neonatal outcomes in pregnancies complicated by T1D.
    DOI:  https://doi.org/10.1055/a-2625-6437
  12. ArXiv. 2025 May 12. pii: arXiv:2505.08821v1. [Epub ahead of print]
      Accurate blood glucose prediction can enable novel interventions for type 1 diabetes treatment, including personalized insulin and dietary adjustments. Although recent advances in transformer-based architectures have demonstrated the power of attention mechanisms in complex multivariate time series prediction, their potential for blood glucose (BG) prediction remains underexplored. We present a comparative analysis of transformer models for multi-horizon BG prediction, examining forecasts up to 4 hours and input history up to 1 week. The publicly available DCLP3 dataset (n=112) was split (80%-10%-10%) for training, validation, and testing, and the OhioT1DM dataset (n=12) served as an external test set. We trained networks with point-wise, patch-wise, series-wise, and hybrid embeddings, using CGM, insulin, and meal data. For short-term blood glucose prediction, Crossformer, a patch-wise transformer architecture, achieved a superior 30-minute prediction of RMSE (15.6 mg / dL on OhioT1DM). For longer-term predictions (1h, 2h, and 4h), PatchTST, another path-wise transformer, prevailed with the lowest RMSE (24.6 mg/dL, 36.1 mg/dL, and 46.5 mg/dL on OhioT1DM). In general, models that used tokenization through patches demonstrated improved accuracy with larger input sizes, with the best results obtained with a one-week history. These findings highlight the promise of transformer-based architectures for BG prediction by capturing and leveraging seasonal patterns in multivariate time-series data to improve accuracy.